Clareo Health | Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian Cancer
Histologically or cytologically confirmed diagnosis of advanced ovarian cancer (FIGO stage III or IV)
PARP inhibitors -naive patient who need to initiate maintenance treatment with PARP inhibitors for the first time (according the the marketing authorization)
Patient with a life expectancy of more then 3 months
Informed patient which does not oppose to participate to the study
* Basal cell carcinoma or non-invasive cutaneous squamous cell carcinoma
* Stage 1B or less cervical carcinoma
* Non-invasive superficial bladder cancer
You may not be if
Prior treatment with PARP inhibitors
Patient incapable to take oral tablets/capsules
Participation in a drug trial that does not authorize concurrent participation in another trials
Person unable to attend scheduled examinations/appointments as part of routine care for geographical, social or psychological reasons
